ABBV-637
- Generic Name
- ABBV-637
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1
Recruiting
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06934889
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Tumors CancerNon Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 81
- Registration Number
- NCT04721015
- Locations
- 🇯🇵
Duplicate_National Hospital Organization Shikoku Cancer Center /ID# 240821, Matsuyama-shi, Ehime, Japan
🇺🇸Dana-Farber Cancer Institute /ID# 231209, Boston, Massachusetts, United States
🇺🇸Washington University-School of Medicine /ID# 225698, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath